Breaking News Instant updates and real-time market news.

APPS

Digital Turbine

$60.91 /

-1.09 (-1.76%)

14:03
01/27/21
01/27
14:03
01/27/21
14:03

Digital Turbine price target raised to $70 from $42 at Roth Capital

Roth Capital analyst Darren Aftahi raised the firm's price target on Digital Turbine to $70 from $42, stating that Google Play download data continued to show increased mobile adoption in Q4 along with signs that the broader advertising market was "very healthy" in the quarter. The analyst, whose checks point to "outsized gains" from e-commerce apps this holiday season along with continued streaming download strength, keeps a Buy rating on Digital Turbine shares.

  • 03

    Feb

APPS Digital Turbine
$60.91 /

-1.09 (-1.76%)

01/22/21 Maxim
Digital Turbine initiated with a Buy at Maxim
12/21/20 Canaccord
Digital Turbine downgraded to Hold from Buy at Canaccord
12/17/20 Craig-Hallum
Digital Turbine price target raised to $60 from $44 at Craig-Hallum
11/18/20 Craig-Hallum
Digital Turbine price target raised to $44 from $38 at Craig-Hallum

TODAY'S FREE FLY STORIES

Hot Stocks
CureVac and Novartis in initial pact on Covid vaccine candidate » 07:31
03/04/21
03/04
07:31
03/04/21
07:31
CVAC

CureVac

$83.44 /

-9.76 (-10.47%)

, NVS

Novartis

$84.16 /

-0.635 (-0.75%)

CureVac (CVAC) and…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CVAC CureVac
$83.44 /

-9.76 (-10.47%)

NVS Novartis
$84.16 /

-0.635 (-0.75%)

CVAC CureVac
$83.44 /

-9.76 (-10.47%)

01/07/21 Morgan Stanley
CureVac COVID-19 deal provides 'sentiment boost' for Bayer, says Morgan Stanley
12/10/20 Credit Suisse
CureVac downgraded to Underperform on rising valuation at Credit Suisse
12/10/20 Credit Suisse
CureVac downgraded to Underperform from Neutral at Credit Suisse
11/02/20 Piper Sandler
CureVac's positive vaccine data bodes well for Arcturus's ARCT-021, says Piper
NVS Novartis
$84.16 /

-0.635 (-0.75%)

03/01/21 Oppenheimer
Homology Medicines loses potential source of upside, says Oppenheimer
02/02/21 Morgan Stanley
Novartis price target lowered to CHF 102 from CHF 104 at Morgan Stanley
02/01/21 Truist
iRhythm price target lowered to $220 from $265 at Truist
02/01/21 Cowen
Novartis downgraded to Market Perform after 'tepid' guidance at Cowen
NVS Novartis
$84.16 /

-0.635 (-0.75%)

  • 28
    Jan
  • 14
    Aug
CVAC CureVac
$83.44 /

-9.76 (-10.47%)

NVS Novartis
$84.16 /

-0.635 (-0.75%)

CVAC CureVac
$83.44 /

-9.76 (-10.47%)

NVS Novartis
$84.16 /

-0.635 (-0.75%)

CVAC CureVac
$83.44 /

-9.76 (-10.47%)

Hot Stocks
Dyne Therapeutics appoints Wildon Farwell as CMO » 07:30
03/04/21
03/04
07:30
03/04/21
07:30
DYN

Dyne Therapeutics

$16.73 /

-1.02 (-5.75%)

, BIIB

Biogen

$266.84 /

-3.2 (-1.19%)

Dyne Therapeutics (DYN)…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DYN Dyne Therapeutics
$16.73 /

-1.02 (-5.75%)

BIIB Biogen
$266.84 /

-3.2 (-1.19%)

DYN Dyne Therapeutics
$16.73 /

-1.02 (-5.75%)

02/09/21
Dyne Therapeutics initiated with a Buy at JonesTrading
01/07/21 Piper Sandler
Dyne Therapeutics potential beneficiary of Sarepta's SRP-9001 miss, says Piper
10/12/20 Jefferies
Dyne Therapeutics initiated with a Buy at Jefferies
10/12/20 JPMorgan
Dyne Therapeutics initiated with an Overweight at JPMorgan
BIIB Biogen
$266.84 /

-3.2 (-1.19%)

02/17/21 Cantor Fitzgerald
Biogen price target lowered to $268 from $278 at Cantor Fitzgerald
02/08/21 Citi
Expert sees Biogen aducanumab approval 50/50 at best, says Citi
02/04/21 SVB Leerink
Biogen price target lowered to $380 from $430 at SVB Leerink
02/04/21 Credit Suisse
Biogen price target lowered to $338 from $350 at Credit Suisse
DYN Dyne Therapeutics
$16.73 /

-1.02 (-5.75%)

BIIB Biogen
$266.84 /

-3.2 (-1.19%)

  • 21
    Jan
  • 17
    Sep
BIIB Biogen
$266.84 /

-3.2 (-1.19%)

DYN Dyne Therapeutics
$16.73 /

-1.02 (-5.75%)

BIIB Biogen
$266.84 /

-3.2 (-1.19%)

BIIB Biogen
$266.84 /

-3.2 (-1.19%)

BIIB Biogen
$266.84 /

-3.2 (-1.19%)

Downgrade
Regency Centers downgraded to Hold from Buy at Argus » 07:29
03/04/21
03/04
07:29
03/04/21
07:29
REG

Regency Centers

$56.67 /

+2.525 (+4.66%)

Argus analyst Angus…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
REG Regency Centers
$56.67 /

+2.525 (+4.66%)

REG Regency Centers
$56.67 /

+2.525 (+4.66%)

07:27 Today Argus
Regency Centers downgraded to Hold from Buy at Argus
01/25/21 Compass Point
Regency Centers upgraded to Buy from Neutral at Compass Point
12/30/20 Truist
Regency Centers price target raised to $50 from $45 at Truist
08/19/20
Fly Intel: Top five analyst downgrades
REG Regency Centers
$56.67 /

+2.525 (+4.66%)

REG Regency Centers
$56.67 /

+2.525 (+4.66%)

Initiation
Open Lending initiated with an Outperform at William Blair » 07:29
03/04/21
03/04
07:29
03/04/21
07:29
LPRO

Open Lending

$38.72 /

-1.3 (-3.25%)

William Blair analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LPRO Open Lending
$38.72 /

-1.3 (-3.25%)

LPRO Open Lending
$38.72 /

-1.3 (-3.25%)

02/10/21 Needham
Open Lending initiated with a Buy at Needham
01/20/21 DA Davidson
Open Lending price target raised to $45 from $31 at DA Davidson
01/04/21 Deutsche Bank
Open Lending named 'Catalyst Call: Buy Idea' at Deutsche Bank
01/04/21 Stephens
Brinker, LiveRamp and Vonage among 2021 best ideas at Stephens
  • 10
    Dec
LPRO Open Lending
$38.72 /

-1.3 (-3.25%)

Hot Stocks
Hookipa Pharma announces publication on alternating 2-vector cancer therapeutics » 07:29
03/04/21
03/04
07:29
03/04/21
07:29
HOOK

Hookipa Pharma

$12.00 /

+0.05 (+0.42%)

HOOKIPA Pharma announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
HOOK Hookipa Pharma
$12.00 /

+0.05 (+0.42%)

HOOK Hookipa Pharma
$12.00 /

+0.05 (+0.42%)

11/30/20 JMP Securities
Hookipa Pharma price target raised to $25 from $19 at JMP Securities
11/03/20
Fly Intel: Top five analyst initiations
11/03/20 Truist
Hookipa Pharma initiated with a Buy at Truist
11/03/20 Truist
Hookipa Pharma initiated with a Buy at Truist
HOOK Hookipa Pharma
$12.00 /

+0.05 (+0.42%)

  • 09
    Dec
HOOK Hookipa Pharma
$12.00 /

+0.05 (+0.42%)

Upgrade
Williams upgraded to Outperform from Sector Perform at Scotiabank » 07:29
03/04/21
03/04
07:29
03/04/21
07:29
WMB

Williams

$23.73 /

+0.02 (+0.08%)

Scotiabank analyst Alonso…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
WMB Williams
$23.73 /

+0.02 (+0.08%)

WMB Williams
$23.73 /

+0.02 (+0.08%)

02/24/21 Mizuho
Williams price target raised to $27 from $26 at Mizuho
01/20/21 Mizuho
Williams price target raised to $26 from $24 at Mizuho
12/17/20 Credit Suisse
Williams upgraded to Outperform from Neutral at Credit Suisse
12/11/20 Morgan Stanley
Morgan Stanley upgrades midstream industry view to Attractive, shakes up ratings
WMB Williams
$23.73 /

+0.02 (+0.08%)

WMB Williams
$23.73 /

+0.02 (+0.08%)

WMB Williams
$23.73 /

+0.02 (+0.08%)

Hot Stocks
Landos Biopharma says all endpoints in Phase 1 study of NX-13 met » 07:28
03/04/21
03/04
07:28
03/04/21
07:28
LABP

Landos Biopharma

$15.22 /

+0.73 (+5.04%)

Landos Biopharma…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
LABP Landos Biopharma
$15.22 /

+0.73 (+5.04%)

LABP Landos Biopharma
$15.22 /

+0.73 (+5.04%)

03/01/21 Jefferies
Landos Biopharma initiated with a Buy at Jefferies
03/01/21 JPMorgan
Landos Biopharma initiated with a Neutral at JPMorgan
03/01/21 Raymond James
Landos Biopharma initiated with an Outperform at Raymond James
03/01/21 SVB Leerink
Landos Biopharma initiated with an Outperform at SVB Leerink
  • 04
    Feb
LABP Landos Biopharma
$15.22 /

+0.73 (+5.04%)

Downgrade
Regency Centers downgraded to Hold from Buy at Argus » 07:27
03/04/21
03/04
07:27
03/04/21
07:27
REG

Regency Centers

$56.67 /

+2.525 (+4.66%)

Argus analyst Jacob…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
REG Regency Centers
$56.67 /

+2.525 (+4.66%)

REG Regency Centers
$56.67 /

+2.525 (+4.66%)

01/25/21 Compass Point
Regency Centers upgraded to Buy from Neutral at Compass Point
12/30/20 Truist
Regency Centers price target raised to $50 from $45 at Truist
08/19/20
Fly Intel: Top five analyst downgrades
08/19/20 Compass Point
Compass Point downgrades Regency Centers on 'tactical valuation call'
REG Regency Centers
$56.67 /

+2.525 (+4.66%)

REG Regency Centers
$56.67 /

+2.525 (+4.66%)

Hot Stocks
NewAge enters LOI to acquire Japan-based Aliven for approx. 1M shares » 07:26
03/04/21
03/04
07:26
03/04/21
07:26
NBEV

NewAge

$2.82 /

-0.1 (-3.43%)

NewAge announced that it…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
NBEV NewAge
$2.82 /

-0.1 (-3.43%)

NBEV NewAge
$2.82 /

-0.1 (-3.43%)

07/21/20 Alliance Global Partners
New Age Beverages price target raised to $5 from $3.50 at Alliance Global
04/14/20 Alliance Global Partners
New Age Beverages at Alliance Global Partners
03/11/20 Compass Point
New Age Beverages price target lowered to $4 from $9 at Compass Point
NBEV NewAge
$2.82 /

-0.1 (-3.43%)

NBEV NewAge
$2.82 /

-0.1 (-3.43%)

Recommendations
Main Street price target raised to $40 from $34 at RBC Capital » 07:25
03/04/21
03/04
07:25
03/04/21
07:25
MAIN

Main Street

$37.33 /

+0.63 (+1.72%)

RBC Capital analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MAIN Main Street
$37.33 /

+0.63 (+1.72%)

MAIN Main Street
$37.33 /

+0.63 (+1.72%)

08/12/20 Truist
Main Street price target raised to $33 from $28 at Truist
04/15/20 National Securities
Main Street downgraded to Neutral from Buy at National Securities
03/17/20 National Securities
Main Street upgraded to Buy from Neutral at National Securities
MAIN Main Street
$37.33 /

+0.63 (+1.72%)

Recommendations
Exxon Mobil price target raised to $60 from $57 at Morgan Stanley » 07:25
03/04/21
03/04
07:25
03/04/21
07:25
XOM

Exxon Mobil

$56.52 /

+0.45 (+0.80%)

Morgan Stanley analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
XOM Exxon Mobil
$56.52 /

+0.45 (+0.80%)

XOM Exxon Mobil
$56.52 /

+0.45 (+0.80%)

07:13 Today Truist
Exxon Mobil price target raised to $60 from $50 at Truist
06:14 Today Citi
Exxon Mobil price target raised to $53 from $44 at Citi
03/02/21 Wells Fargo
Exxon Mobil price target raised to $65 from $53 at Wells Fargo
02/26/21 Barclays
Exxon Mobil price target raised to $65 from $59 at Barclays
XOM Exxon Mobil
$56.52 /

+0.45 (+0.80%)

XOM Exxon Mobil
$56.52 /

+0.45 (+0.80%)

XOM Exxon Mobil
$56.52 /

+0.45 (+0.80%)

XOM Exxon Mobil
$56.52 /

+0.45 (+0.80%)

Hot Stocks
VBL Therapeutics announces publication of interim analysis of OVAL study » 07:24
03/04/21
03/04
07:24
03/04/21
07:24
VBLT

VBL Therapeutics

$1.83 /

-0.12 (-6.15%)

VBL Therapeutics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VBLT VBL Therapeutics
$1.83 /

-0.12 (-6.15%)

VBLT VBL Therapeutics
$1.83 /

-0.12 (-6.15%)

01/28/21 H.C. Wainwright
VBL Therapeutics price target raised to $4 from $3 at H.C. Wainwright
VBLT VBL Therapeutics
$1.83 /

-0.12 (-6.15%)

VBLT VBL Therapeutics
$1.83 /

-0.12 (-6.15%)

Hot Stocks
Fulcrum Therapeutics CEO Robert Gould to retire, Bryan Stuart to succeed » 07:23
03/04/21
03/04
07:23
03/04/21
07:23
FULC

Fulcrum Therapeutics

$14.59 /

+0.59 (+4.21%)

Fulcrum Therapeutics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
FULC Fulcrum Therapeutics
$14.59 /

+0.59 (+4.21%)

FULC Fulcrum Therapeutics
$14.59 /

+0.59 (+4.21%)

03/01/21 Stifel
Fulcrum Therapeutics initiated with a Buy at Stifel
10/15/20 Piper Sandler
Fulcrum Therapeutics initiated with an Overweight at Piper Sandler
08/12/20
Fly Intel: Top five analyst downgrades
08/12/20 BTIG
Fulcrum Therapeutics price target lowered to $22 from $27 at BTIG
FULC Fulcrum Therapeutics
$14.59 /

+0.59 (+4.21%)

  • 20
    Jan
Recommendations
General Electric price target raised to $17 from $13 at Morgan Stanley » 07:22
03/04/21
03/04
07:22
03/04/21
07:22
GE

General Electric

$13.45 /

+0.48 (+3.70%)

Morgan Stanley analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GE General Electric
$13.45 /

+0.48 (+3.70%)

GE General Electric
$13.45 /

+0.48 (+3.70%)

03/02/21 Barclays
Danaher started at Overweight at Barclays on GE biopharma business potential
02/22/21 Goldman Sachs
General Electric price target raised to $15 at Goldman Sachs after meetings
01/28/21 Barclays
General Electric price target raised to $13 from $12 at Barclays
01/27/21 Morgan Stanley
General Electric price target raised to $13 from $12 at Morgan Stanley
GE General Electric
$13.45 /

+0.48 (+3.70%)

GE General Electric
$13.45 /

+0.48 (+3.70%)

GE General Electric
$13.45 /

+0.48 (+3.70%)

GE General Electric
$13.45 /

+0.48 (+3.70%)

Hot Stocks
DeepGreen Metals enters $2.9B combination agreement with SOAC » 07:22
03/04/21
03/04
07:22
03/04/21
07:22
SOAC

Sustainable Opportunities Acquisition Corp.

$10.22 /

-0.2 (-1.92%)

DeepGreen Metals …

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SOAC Sustainable Opportunities Acquisition Corp.
$10.22 /

-0.2 (-1.92%)

SOAC Sustainable Opportunities Acquisition Corp.
$10.22 /

-0.2 (-1.92%)

Hot Stocks
Kronos Bio to initiate Phase 3 trial of entospletinib in mid-2021 » 07:21
03/04/21
03/04
07:21
03/04/21
07:21
KRON

Kronos Bio

$28.75 /

-0.66 (-2.24%)

Kronos Bio announced,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
KRON Kronos Bio
$28.75 /

-0.66 (-2.24%)

KRON Kronos Bio
$28.75 /

-0.66 (-2.24%)

11/03/20
Fly Intel: Top five analyst initiations
11/03/20 Jefferies
Kronos Bio initiated with a Buy at Jefferies
11/03/20 Piper Sandler
Kronos Bio initiated with an Overweight at Piper Sandler
11/03/20 Goldman Sachs
Kronos Bio initiated with a Buy at Goldman Sachs
KRON Kronos Bio
$28.75 /

-0.66 (-2.24%)

  • 09
    Oct
KRON Kronos Bio
$28.75 /

-0.66 (-2.24%)

KRON Kronos Bio
$28.75 /

-0.66 (-2.24%)

Hot Stocks
Sol-Gel Technologies expects cash to fund requirements into 3Q22 » 07:20
03/04/21
03/04
07:20
03/04/21
07:20
SLGL

Sol-Gel Technologies

$9.58 /

-0.05 (-0.52%)

As of December 31, 2020,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SLGL Sol-Gel Technologies
$9.58 /

-0.05 (-0.52%)

SLGL Sol-Gel Technologies
$9.58 /

-0.05 (-0.52%)

03/26/20 H.C. Wainwright
Sol-Gel Technologies price target lowered to $21 from $26 at H.C. Wainwright
SLGL Sol-Gel Technologies
$9.58 /

-0.05 (-0.52%)

SLGL Sol-Gel Technologies
$9.58 /

-0.05 (-0.52%)

Hot Stocks
Shift4 Payments announces acquisition of VenueNext, terms undisclosed » 07:19
03/04/21
03/04
07:19
03/04/21
07:19
FOUR

Shift4 Payments

$71.06 /

-4.24 (-5.63%)

Shift4 Payments announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
FOUR Shift4 Payments
$71.06 /

-4.24 (-5.63%)

FOUR Shift4 Payments
$71.06 /

-4.24 (-5.63%)

01/06/21 Wolfe Research
Shift4 Payments downgraded to Peer Perform from Outperform at Wolfe Research
01/06/21 BofA
Shift4 Payments double-downgraded to Underperform from Buy at BofA
12/21/20
Fly Intel: Top five analyst initiations
12/21/20 Piper Sandler
Shift4 Payments initiated with an Overweight at Piper Sandler
FOUR Shift4 Payments
$71.06 /

-4.24 (-5.63%)

  • 03
    Dec
  • 11
    Sep
  • 05
    Jun
FOUR Shift4 Payments
$71.06 /

-4.24 (-5.63%)

FOUR Shift4 Payments
$71.06 /

-4.24 (-5.63%)

Earnings
Sol-Gel Technologies reports 2020 EPS ($1.30), consensus ($1.48) » 07:19
03/04/21
03/04
07:19
03/04/21
07:19
SLGL

Sol-Gel Technologies

$9.58 /

-0.05 (-0.52%)

Reports 2020 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SLGL Sol-Gel Technologies
$9.58 /

-0.05 (-0.52%)

SLGL Sol-Gel Technologies
$9.58 /

-0.05 (-0.52%)

03/26/20 H.C. Wainwright
Sol-Gel Technologies price target lowered to $21 from $26 at H.C. Wainwright
SLGL Sol-Gel Technologies
$9.58 /

-0.05 (-0.52%)

SLGL Sol-Gel Technologies
$9.58 /

-0.05 (-0.52%)

Downgrade
Retail Properties of America downgraded to Sector Weight at KeyBanc » 07:18
03/04/21
03/04
07:18
03/04/21
07:18
RPAI

Retail Properties of America

$10.99 /

+0.51 (+4.87%)

As previously reported,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RPAI Retail Properties of America
$10.99 /

+0.51 (+4.87%)

RPAI Retail Properties of America
$10.99 /

+0.51 (+4.87%)

05:20 Today KeyBanc
Retail Properties downgraded to Sector Weight from Overweight at KeyBanc
12/15/20 Citi
Retail Properties of America price target raised to $9.50 from $7 at Citi
11/10/20 Compass Point
Compass Point upgrades four retail REITs to Neutral after Pfizer 'game changer'
11/09/20 Compass Point
Retail Properties of America upgraded to Neutral from Sell at Compass Point
RPAI Retail Properties of America
$10.99 /

+0.51 (+4.87%)

Hot Stocks
Fulcrum Therapeutics expects cash to fund requirements into 4Q22 » 07:16
03/04/21
03/04
07:16
03/04/21
07:16
FULC

Fulcrum Therapeutics

$14.59 /

+0.59 (+4.21%)

The company said,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
FULC Fulcrum Therapeutics
$14.59 /

+0.59 (+4.21%)

FULC Fulcrum Therapeutics
$14.59 /

+0.59 (+4.21%)

03/01/21 Stifel
Fulcrum Therapeutics initiated with a Buy at Stifel
10/15/20 Piper Sandler
Fulcrum Therapeutics initiated with an Overweight at Piper Sandler
08/12/20
Fly Intel: Top five analyst downgrades
08/12/20 BTIG
Fulcrum Therapeutics price target lowered to $22 from $27 at BTIG
FULC Fulcrum Therapeutics
$14.59 /

+0.59 (+4.21%)

  • 20
    Jan
Upgrade
Site Centers upgraded to Overweight at KeyBanc » 07:16
03/04/21
03/04
07:16
03/04/21
07:16
SITC

Site Centers

$12.89 /

+0.1 (+0.78%)

As previously reported,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SITC Site Centers
$12.89 /

+0.1 (+0.78%)

SITC Site Centers
$12.89 /

+0.1 (+0.78%)

05:19 Today KeyBanc
Site Centers upgraded to Overweight from Sector Weight at KeyBanc
02/23/21 Mizuho
Site Centers price target raised to $13 from $10.50 at Mizuho
01/14/21 Piper Sandler
Site Centers upgraded to Overweight from Neutral at Piper Sandler
12/15/20 Citi
Site Centers price target raised to $11 from $8.50 at Citi
SITC Site Centers
$12.89 /

+0.1 (+0.78%)

  • 02
    Mar
Hot Stocks
Fulcrum Therapeutics decides to discontinue LOSVID Phase 3 trial » 07:16
03/04/21
03/04
07:16
03/04/21
07:16
FULC

Fulcrum Therapeutics

$14.59 /

+0.59 (+4.21%)

After careful…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
FULC Fulcrum Therapeutics
$14.59 /

+0.59 (+4.21%)

FULC Fulcrum Therapeutics
$14.59 /

+0.59 (+4.21%)

03/01/21 Stifel
Fulcrum Therapeutics initiated with a Buy at Stifel
10/15/20 Piper Sandler
Fulcrum Therapeutics initiated with an Overweight at Piper Sandler
08/12/20
Fly Intel: Top five analyst downgrades
08/12/20 BTIG
Fulcrum Therapeutics price target lowered to $22 from $27 at BTIG
FULC Fulcrum Therapeutics
$14.59 /

+0.59 (+4.21%)

  • 20
    Jan
Initiation
Wheaton Precious Metals initiated with an Overweight at JPMorgan » 07:16
03/04/21
03/04
07:16
03/04/21
07:16
WPM

Wheaton Precious Metals

$35.82 /

-1.05 (-2.85%)

JPMorgan analyst Tyler…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
WPM Wheaton Precious Metals
$35.82 /

-1.05 (-2.85%)

WPM Wheaton Precious Metals
$35.82 /

-1.05 (-2.85%)

03/01/21 Berenberg
Wheaton Precious Metals price target raised to 3,700 GBp at Berenberg
02/16/21 Berenberg
Wheaton Precious Metals price target lowered to 3,500 GBp from 3,700 GBp at Berenberg
02/08/21 Stifel
Wheaton Precious Metals upgraded to Buy from Hold at Stifel
02/02/21 Credit Suisse
Wheaton Precious Metals price target lowered to C$62 from C$64 at Credit Suisse
WPM Wheaton Precious Metals
$35.82 /

-1.05 (-2.85%)

WPM Wheaton Precious Metals
$35.82 /

-1.05 (-2.85%)

WPM Wheaton Precious Metals
$35.82 /

-1.05 (-2.85%)

WPM Wheaton Precious Metals
$35.82 /

-1.05 (-2.85%)

Earnings
Fulcrum Therapeutics reports Q4 EPS (64c), consensus (72c) » 07:15
03/04/21
03/04
07:15
03/04/21
07:15
FULC

Fulcrum Therapeutics

$14.59 /

+0.59 (+4.21%)

Reports Q4 revenue $4.2M,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
FULC Fulcrum Therapeutics
$14.59 /

+0.59 (+4.21%)

FULC Fulcrum Therapeutics
$14.59 /

+0.59 (+4.21%)

03/01/21 Stifel
Fulcrum Therapeutics initiated with a Buy at Stifel
10/15/20 Piper Sandler
Fulcrum Therapeutics initiated with an Overweight at Piper Sandler
08/12/20
Fly Intel: Top five analyst downgrades
08/12/20 BTIG
Fulcrum Therapeutics price target lowered to $22 from $27 at BTIG
FULC Fulcrum Therapeutics
$14.59 /

+0.59 (+4.21%)

  • 20
    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.